Par Drugs And Chemicals Limited · NSE:PAR
Par Drugs And Chemicals — H1 FY2022 Earnings Presentation
16 slides from Par Drugs And Chemicals's earnings presentation, Nov 16, 2021
Slide 1: Cover letter to NSE on Investors Presentation
PAR/CS/NSE/2020-21/41 PAR/CS/NSE/2021-22/51 To, Date: 16/11/2021 The Manager Listing department, National Stock Exchange of India Limited Exchange Plaza, C-1, Block-G, Bandra Kurla Complex, Bandra (E), Mumbai- 400 051 Maharashtra Symbol - PAR, ISIN: INE04LG01015 Subject: Investors Presentation Ref.:
Slide 2: H1/Q2-FY22 Earnings Presentation
H1/Q2-FY22 Earnings Presentation
Slide 3: Company Overview
Company Overview
Slide 4: Company Overview
3 Company Overview Operational Revenues (INR Mn) • Promoted by Mr. Falgun Savani and Mr. Jignesh Savani, Par Drugs and Chemicals Limited (PDCL) was founded in 1982 and is engaged in the development 194 218 and manufacturing of APIs. 164 199 134 100 • The Company today manufactures more than 28 diffe
Slide 5: Key Strengths
4 Key Strengths Diversified Portfolio: The company manufactures the entire range of products in the Antacid segment. The product portfolio presently comprises 18 APIs and 10 Fine Chemicals which are marketed domestically and exported. Global Presence: The Company is operating both in domestic and ex
Slide 6: Financial & Operational Highlights
FINANCIAL & OPERATIONAL HIGHLIGHTS
Slide 7: H1/Q2-FY22 Financial & Operational Highlights
6 H1/Q2-FY22 Financial & Operational Highlights Q2-FY22 Financial Highlights Operational Highlights • Since the beginning of the financial year we are facing the Revenue EBITDA EBITDA Margin Price Rise of Indonesian Coal. The same we were not able to INR 196 Mn INR 40 Mn 20.41% pass it on the custom
Slide 8: H1/Q2-FY22 Financial Overview
H1/Q2-FY22 Financial Overview
Slide 9: Q2-FY22 Income Statement (IND-AS)
8 Q2-FY22 Income Statement (IND-AS) Income Statement (INR Mn) Q2-FY22 Q2-FY21 Y-o-Y Q1-FY22 Q-o-Q Income from Operations 196 172 14.0% 165 18.8% Total Expenses 156 121 28.9% 124 25.8% EBITDA 40 51 (21.6)% 41 (2.4)% EBITDA Margin 20.41% 29.65% (924) Bps 24.85% (444) Bps Finance Cost 2 3 (33.3)% - NA
Slide 10: H1-FY22 Income statement (IND-AS)
9 H1-FY22 Income statement (IND-AS) Income Statement (INR Mn) H1-FY22 H1-FY21 Y-o-Y Income from Operations 361 283 27.6% Total Expenses 279 205 36.1% EBITDA 82 78 5.1% EBITDA Margin 22.71% 27.56% (485) Bps Finance Cost 3 4 (25)% Depreciation 17 15 6.7% Other Income 1 1 NA Profit before Extra Ordinar
Slide 11: Historical Income statement
10 Historical Income statement Income Statement (INR Mn) FY19 FY20 FY21 H1-FY22 Income from Operations 463 558 607 361 Total Expenses 381 464 448 279 EBITDA 82 94 159 82 EBITDA Margin 17.71% 16.85% 26.19% 22.71% Finance Cost 20 8 6 3 Depreciation 30 27 28 17 Other Income 1 1 2 1 Profit before Extra
Slide 12: Balance Sheet
11 Balance Sheet EQUITIES & LIABILITIES (INR Mn) FY20 FY21 H1-FY22 ASSETS (INR Mn) FY20 FY21 H1-FY22 Shareholder Funds 406 523 569 Non Current Assets 359 352 352 (A) Equity Share Capital 61 62 123 (A) Fixed Assets (B) Reserves & Surplus 345 461 446 (i) Tangible Assets 344 299 344 (ii) Capital work-i
Slide 13: Financial Highlights
12 Financial Highlights Operational Revenue (INR Mn) EBITDA (INR Mn) & EBITDA Margins (%) PAT (INR Mn) & PAT Margins (%) 26.19% 607 22.71% 19.11% 558 463 18.87% 17.71% 424 16.85% 13.02% 361 8.60% 5.40% 3.54% 80 82 94 159 82 25 48 116 47 15 FY18 FY19 FY20 FY21 H1-FY22 FY18 FY19 FY20 FY21 H1-FY22 FY18
Slide 14: Capital Market Highlights
13 Capital Market Highlights Price Data (30th September, 2021) INR Shareholding Pattern as on 30th September, 2021 Face Value 10.0 Market Price 210.45 Public 26% 52 Week High/Low 210.45/49.00 Market Cap (Mn) 2,589.5 Promoters 52 74% Equity Shares Outstanding (Mn)** 12.3 1 Year Avg Trading Volume (‘0
Slide 15: Disclaimer
14 Disclaimer Par Drugs and Chemicals Limited: The above Presentation with slides have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection w
Slide 16: Thank You
Thank You
Par Drugs and Chemicals — H1 FY2022 Earnings Presentation on 6ix